With so many biosimilars in the pipeline, the federal government has its hands full. To better understand what Fall has in store, we spoke with Dr. Sarfaraz Niazi.
JSR Life Sciences, LLC ("JSR") today announced that Similis Bio ("Similis"), its business unit focused on biosimilar development, has announced plans to enter into a partnership with Novel351k to co-develop
A Bill signed today allows waivers of animal testing for new drugs and biosimilars, a major shift in how the drug development with lower cost and better safety.